Call Us: 1.800.873.5297

By

FDA Warns of Rare, But Potentially Fatal, Skin Reactions with Ziprasidone

On December 11, 2014, the Food and Drug Administration (FDA) issued a Drug Safety Communication warning that the antipsychotic drug Ziprasidone (brand name, Geodon), which is used to treat schizophrenia and bipolar disorder, is associated with rare, but potentially fatal, serious skin reactions that can affect other parts of the body. The FDA reports that […]

By

JPML Decides to Centralize Cases Involving Syngenta Corporation in Kansas (MDL 2591)

Law360 reports that the Judicial Panel on Multidistrict Litigation (JPML) has agreed to centralize 177 lawsuits filed against Syngenta Corporation in the District of Kansas (In re: Syngenta AG MIR162 Corn Litigation, MDL 2591). The JPML said that it chose the District of Kansas because it is “readily accessible”, and assigned the MDL to Judge […]

By

Judge Says Transvaginal Mesh Manufacturer C.R. Bard Faces Billions in Verdicts, Bloomberg Reports

Bloomberg reports that Judge Joseph Goodwin, the federal judge overseeing the C.R. Bard Multidistrict Litigation (MDL 2187) in West Virginia, “took the unusual step of urging C.R. Bard to settle thousands of lawsuits over defective vaginal-mesh implants because juries may award billions of dollars in damages.” Judge Goodwin said during a December 9th hearing, “I […]

By

Xarelto® Lawsuit (MDL 2592) Update: JPML Centralizes MDL in Louisiana

On October 9, 2014, and on behalf of six plaintiffs, Roger Denton of Schlichter, Bogard & Denton, LLP filed a petition with the Judicial Panel on Multidistrict Litigation (JPML) requesting that all federally-filed Xarelto® cases be consolidated for coordinated pretrial proceedings. On December 4, 2014, a hearing before five federal judges on the Multidistrict Litigation […]

By

Transvaginal Mesh (MDL 2326) Update: Cases Against Boston Scientific Move Forward After First Two Bellwether Trials

Cases against Boston Scientific continue to move forward in the Multidistrict Litigation (In re: Boston Scientific Corp. Pelvic Repair System Products Liability Litigation, MDL 2326) before The Honorable Judge Joseph R. Goodwin in the United States District Court for the Southern District of West Virginia. According to the Court’s most recent Pretrial Order, new deadlines […]

By

Takata Has Struggled to Tame Airbag Compound for Decades, The New York Time Reports

The New York Times reports that Takata has struggled for nearly two decades to tame an unstable compound that is thought to be the source of airbag ruptures. According to The New York Times, “[a]s far back as June 1995, a patent application filed by Takata expressed concern over using the compound, saying that it […]

By

Gynecologists Continue Using Power Morcellators Despite FDA Warning, The Wall Street Journal Reports

The Wall Street Journal reports that doctors nationwide are continuing to use a popular surgical tool, known as power morcellators, even after the United States Food and Drug Administration (FDA) warned that the device can spread undetected cancer. The Wall Street Journal notes that this demonstrates “the limits of the regulator’s reach into clinical practice.” In […]

By

Financial Ties Between FDA Advisory Committee Members and Companies Not Always Disclosed, The Wall Street Journal Reports

An analysis by The Wall Street Journal shows that the United States Food and Drug Administration (FDA) does not always disclose financial ties between members of its medical device advisory committee and the companies that manufacturer medical devices. In particular, the WSJ analysis found that “a third of advisers on the FDA’s cardiology, orthopedics and […]

By

FDA Issues Safety Announcement regarding Risks of Long-Term Antiplatelet Therapy

The FDA has issued a Safety Announcement regarding the safety information and preliminary data from the Dual Antiplatelet Therapy (DAPT) trial, which was published in the New England Journal of Medicine on November 16, 2014. The FDA stated that it is “evaluating preliminary data from a clinical trial showing that treatment for 30 months with […]

By

TVM Lawsuit Update (MDL 2326): Boston Scientific Ordered by Jury to Pay $18.5 Million in Second Federal Trial

For the second time this month, Boston Scientific has been found liable by a jury in federal court for selling defective vaginal mesh implants, according to the Chicago Tribune. A jury in West Virginia federal court deliberated for six hours before concluding that Boston Scientific failed to adequately warn the four women at issue and […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.